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Introduction
 Despite a trend of decreasing incidence and mortality, 
cervical cancer is a major health problem for Korean 
women. It is estimated that, in 2008, there were 3,888 
new cases, accounting for 4.5% of all new female cancer 
cases. The incidence rate per 100,000 women was 11.2 in 
2008, decreased from a high of 16.3 in 1999. Survival rates 
have also improved (Jung et al., 2011). Both phenomena 
may be due in large part to the introduction of the cervical 
cancer screening programme in Korea in the late 1980s 
(Shin et al., 2008).
 In 1988, Korea introduced population-based cervical 
cancer screening, initially providing this service to 
employees and dependents insured by the Korea National 
Health Insurance Programme. As part of a comprehensive 
10-year plan for cancer control, the National Cancer 
Screening Programme (NCSP) for Medical Aid Programme 
(MAP) recipients was initiated in 1999 (Kim et al., 2011). 
Currently, there are two organised, population-based 
cancer screening programmes in Korea. One is the NCSP, 
whose target population includes MAP recipients and 
National Health Insurance (NHI) beneficiaries in the 
lower 50% of the income bracket, and the other is the NHI 
Cancer Screening Programme (NHICSP), whose target 
population is NHI beneficiaries in the upper 50% of the 
income bracket. These two programmes provide biennial 
1National Cancer Control Institute, National Cancer Centre, Goyang, 2Department of Social Medicine, College of Medicine, 
Dankook University, Cheonan, 3Department of Preventive Medicine, College of Medicine, Chosun University, Gwangju, 4Department 
of Preventive Medicine & Institute of Health Service Research, Yonsei University College of Medicine, Seoul, Korea  *For 
correspondence: jkjun@ncc.re.kr
Abstract
 The National Cancer Screening Programme (NCSP) began in 1999. The purpose of this report is to evaluate 
the results of the NCSP for cervical cancer in 2008 and to present essential evidence associated with the cervical 
cancer screening programme in Korea. Screening results were obtained from the National Cancer Screening 
Information System. Participation rates and recall rates were calculated with 95% confidence intervals (CIs). 
The target population of the cervical cancer screening programme in 2008 was 4,701,167 Korean women aged 30 
and over, 1,208,581 of whom underwent Papanicolaou (Pap) smear tests (25.7% participation rate). The recall 
rate was 0.41% (95% CI, 0.40 to 0.42). Although efforts to facilitate participation and to reduce disparities in 
cervical cancer screening among Korean women are needed, the results do provide 
 support evidence-based strategies for control of cervical cancer in Korea. 
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screening tests free of charge to all Korean women aged 
30 and over. 
 In the present study, we aimed to provide preliminary 
information on cervical cancer screening programmes 
based on data collected by the NCSP in 2008. This 
report describes participation rates and the percentage of 
abnormalities by age and insurance type. The results for 
the NHICSP will be reported by the NHI Corporation.
 
Materials and Methods
 The target population for cervical cancer screening in 
the 2008 NCSP was women born in 1978 or earlier who 
were MAP recipients or NHI beneficiaries in the lower 
50% of the income bracket. For those NHI beneficiaries 
who were included in the NCSP, the insurance premium 
was USD 56.50 or less per month for employees and USD 
67.00 or less per month for the self-employed (based on 
figures from November 2007).
 Using an online database system, we confirmed 
participation in the NCSP by examining the insurance 
claims and results of cervical cancer screening submitted 
to the NHI Corporation before 31 December 2009. 
Screening was performed between 1 January 2008 and 31 
December 2008. Some subjects underwent the screening 
procedure multiple times; for those individuals, only the 
first screening was counted (n = 577). These participants 
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were only counted once in determining the participation 
rate. The participation rate of cervical cancer screening 
was calculated by dividing the number of participants by 
the target population of the NCSP for cervical cancer, and 
it is denoted as a percentage (Perry et al., 2006).  
 The standard modality for cervical cancer screening 
in the NCSP is the Papanicolaou (Pap) smear test, which 
is based on conventional cytology. The NCSP requires 
that units report Pap smear results using the Bethesda 
System categories (Bergeron, 2003). The categories 
included are normal, infection/reaction, atypical squamous 
cells of undetermined significance (ASCUS), low-grade 
squamous intraepithelial lesion (LSIL), high-grade 
squamous intraepithelial lesion (HSIL), squamous cell 
carcinoma, and other. The category “other” includes Pap 
smear results relating only to the glandular elements of 
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the genital tract and to hormonal evaluation. Pap smear 
results were defined as abnormal if they were reported as 
LSIL, HSIL, adenocarcinoma in situ (AIS), or squamous 
or adenomatous cell carcinoma. Recall rates for cervical 
cancer screening were defined as the proportion of 
abnormal cases among the cancer-screened participants. 
The 95% confidence intervals (CIs) were calculated for 
all outcome variables.
Results 
 The target population of the 2008 NCSP for cervical 
cancer screening was 4,701,167 women. Based on 
health insurance, 647,630 (13.8%) were covered by the 
MAP and 4,053,537 (86.2%) were covered by the NHI. 
There were 262,292 over the age of 70 covered by MAP, 
accounting for 40.5% of total MAP recipients. This 
was much higher than the 10.4% of NHI beneficiaries 
falling in the same age group. In the target population, 
a total of 1,208,581 women underwent cervical cancer 
screening. The screening participants included 89,893 
MAP recipients (7.4%) and 1,118,688 NHI beneficiaries 
(92.6%). Participants in their 40s comprised the largest 
group; there were 23,172 (25.8%) MAP recipients and 
386,362 (34.5%) NHI beneficiaries in this age group. The 
number of participants from among the NHI beneficiaries 
decreased with age, whereas the numbers of participants 
from among the MAP recipients did not change with age 
(Figure 1).
  The total participation rate in the 2008 NCSP for 
cervical cancer was 25.7%. The participation rate of 
the NHI beneficiaries (27.6%) was higher than the 
Table 1. Screening Outcomes by Age, Health Insurance Type, and Area of Residence from the National Cancer 
Screening Programme for Cervical Cancer, 2008
            Target (n) Participants (n)    Rate (%) Abnormal cases* (n) Recall rate (%)  (95% C.I.)
Total  4,701,167  1,208,581  25.7  4,996  0.41  (0.40-0.42)
Health insurance type      
  National Health Insurance 4,053,537  1,118,688  27.6  4,330  0.39  (0.38-0.40)
  Medical Aid Programme 647,630  89,893  13.9  696  0.77  (0.72-0.83)
Age group (yr) 30-39 862,107  124,754  14.5  671  0.54  (0.50-0.58)
   40-49 1,428,591  409,532  28.7  1,782  0.44  (0.41-0.46)
   50-59 1,082,933  381,203  35.2  1,284  0.34  (0.32-0.36)
   60-69 644,373  213,414  33.1  799  0.37  (0.35-0.40)
   70+ 683,163  79,678  11.7  460  0.58  (0.52-0.63)
Residence area  Seoul 872,230  222,504  25.5  1,063  0.48  (0.45-0.51)
   Busan 370,775  112,726  30.4  506  0.45  (0.41-0.49)
   Daegu 240,481  72,755  30.3  215  0.30  (0.26-0.33)
   Daejeon 127,867  39,238  30.7  142  0.36  (0.30-0.42)
   Incheon 258,714  58,659  22.7  343  0.58  (0.52-0.65)
   Gwangju 128,180  35,025  27.3  124  0.35  (0.29-0.42)
   Ulsan 81,811  21,547  26.3  98  0.45  (0.36-0.54)
   Gyeonggi 962,831  240,975  25.0  1,053  0.44  (0.41-0.46)
   Gangwon 163,562  40,604  24.8  157  0.39  (0.33-0.45)
   Chungbuk 162,748  42,935  26.4  198  0.46  (0.40-0.53)
   Chungam 214,278  41,271  19.3  129  0.31  (0.26-0.37)
   Jeolbuk 213,645  51,929  24.3  237  0.46  (0.40-0.51)
   Jeolnam 229,559  54,506  23.7  167  0.31  (0.26-0.35)
   Gyeongbuk 293,295  73,832  25.2  226  0.31  (0.27-0.35)
   Gyeongnam 322,546  83,947  26.0  234  0.28  (0.24-0.31)
   Jeju 58,645  16,128  27.5  104  0.64  (0.52-0.77)
*Includes low-grade intraepithelial lesion (LSIL), high-grade intraepithelial lesion (HSIL), adenocarcinoma in situ (AIS), and 
squamous or adenomatous cell cancer
Figure 1. Number of Participants by Health Insurance 
Type and Age from the National Cancer Screening 
Programme for Cervical Cancer, 2008
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participation rate of MAP recipients (13.9%) (Table 1, 
Figure 2). Participation rates increased with age; 36.5% 
of NHI beneficiaries in their 50s and 19.9% of MAP 
recipients in their 60s participated. 
 Table 2 shows the results of the Pap smears. Of 
the 1,208,581 tests performed, 0.41% were abnormal 
(LSIL, HSIL, AIS, or squamous or adenomatous cell 
carcinoma). The U-shaped curve representing abnormal 
tests by age diverged from 0.54% for women in their 30s, 
reached a minimum (0.34%) for women in their 50s, and 
approached 0.58% for women aged 70 and over (Figure 
3). With increasing age, the proportions of LSIL reported 
decreased, and the proportions of HSIL or squamous cell 
carcinoma increased.
 Discussion
Organised screening programmes for cervical cancer 
using Pap smears have been shown to be effective in 
decreasing both the incidence and mortality of the disease 
(Anttila et al., 2004). The NCSP for cervical cancer is a 
nationwide cancer screening programme launched in 1999. 
Since organised cervical cancer screening programmes, 
including the NCSP, were introduced in Korea, both the 
incidence and mortality of cervical cancer have been 
declining steadily (Jun et al., 2009; Shin et al., 2008). The 
incidence of cervical cancer decreased by 4.6% annually 
from 1999 to 2008 (Jung et al., 2011).
The NCSP participation rate for cervical cancer in 
2008 was 25.7%. Although participation rates have been 
increasing, they are still lower than those for other cancer 
screening programmes in the NCSP (Lee et al., 2011; Oh et 
al., 2010; Lee et al., 2010). Both socioeconomic status and 
age affect participation rates. First, both the incidence and 
mortality of cervical cancer are known to be relatively high 
among women of lower socioeconomic status (Kim et al., 
2008); therefore, the participation rate in cervical cancer 
screening needs to be improved in this cohort. However, 
the participation rate of MAP recipients decreased from 
15.4% in 2002 to 13.9% in 2008 (Choi et al., 2010). 
Although the NCSP’s cervical cancer screening is free 
of charge, the poor participation rate of women of lower 
socioeconomic status indicates that other factors inhibit 
participation in cervical cancer screening apart from the 
economic burden of screening costs. Identification of 
barriers to participation in cervical cancer screening and 
solutions to overcome them are required.
Second, the participation rate of women aged 30-39 
was 14.5%. This rate was lower than all other age groups 
except for women aged 70 and over. Although there 
are various recommendations regarding when to start 
screening, it is important that women should be screened 
beginning in their 30s. The incidence of cervical cancer 
in Korea is very low in women under 30 years of age, but 
then begins to climb rapidly thereafter (Jung et al., 2011). 
Some countries, including Korea, have reported increasing 
rates in younger women (Herbert, 2004; Chan et al., 2003; 
Han et al., 2008). For these reasons, we should attempt 
to increase participation in the NCSP for cervical cancer 
	  
Figure 3. Proportion of Abnormal Results by Age 
from the National Cancer Screening Programme for 
Cervical Cancer, 2008
Table 2. Distribution of Papanicolaou (Pap) Smear Test Results by Age Group in the National Cancer Screening 
Programme for Cervical Cancer, 2008
         All                   30−39          40−49       50−59  60−69              70+
                (n=1,208,581)      (n=124,754)        (n=409,532)   (n=381,203)       (n=213,414)        (n=79,678) 
Normal 792,033  (65.3) 82,830 (66.4) 270,103 (66.0) 246,732 (64.7) 139,58 (65.4) 52,783 (66.2)
Epithelial cell abnormality   30,432  (2.5) 3,362  (3.0) 11,471  (2.8)    9,212  (2.4)    4,484  (2.1) 1,903  (2.4)
     Squamous cell   24,336      2,816      9,157      7,251      3,528      1,584  
     Glandular cell 133         5        21        24        37        46       
 Unknown    5,963       541      2,293      1,937       919       273  
  Negative for intraepithelial lesion or malignancy  
  380,403  (31.5)   38,027  (30.5)  125,980  (30.8)  123,435  (32.4)   68,386  (32.0)   24,575  (30.8)
     Organisms  130,343     10,377     41,221     43,903     25,713      9,129  
     Reactive changes  250,060     27,650     84,759     79,532     42,673     15,446  
   Other 5,713 (0.5) 535 (0.4) 1,978  (0.5)    1,824  (0.5)     959  (0.4)     417  (0.5)
Total Abnormals*    4,996  (0.4)     671  (0.5)    1,782  (0.4)    1,284  (0.3)     799  (0.4)     460  (0.6)
Data are n (%); *Includes low-grade intraepithelial lesion (LSIL), high-grade intraepithelial lesion (HSIL), adenocarcinoma in situ 
(AIS), and squamous or adenomatous cell cancer
	  
Figure 2. Participation Rates by Health Insurance 
Type and Age from the National Cancer Screening 
Programme for Cervical Cancer, 2008
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among women in their 30s.
Finally, many countries recommend discontinuing 
cervical cancer screening once women reach their 60s. 
Older women tend to be less compliant with screening 
protocols, and good-quality smears are difficult to obtain 
from women so far past menopause. However, in view 
of the high age-specific incidence of cervical cancer in 
older women, there is controversy in Korea regarding 
when older women should be advised to discontinue 
cervical cancer screening. Although age-standardised 
mortality rates for cervical cancer in Korean women have 
significantly decreased over time, they increased in women 
aged 70 and over by 3.62% annually (Shin et al., 2008). 
Older women in Korea, especially those who have never 
been screened or have not been screened for many years, 
should still be encouraged to get tested. 
In 2008, 25.7% of the target population participated in 
the NCSP for cervical cancer. Differences in participation 
rates occurred between regions, age, and socioeconomic 
status. Thus, along with improving the participation rate in 
cervical cancer screening, continuing efforts are required 
to minimise these differences. Our results can be useful 
to government officials, clinical providers, and public 
health researchers for planning policies and new studies 
to improve efforts to prevent cervical cancer in Korea.
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